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SUMMARY 
Background: Preventable adverse events of medication are an important cause of hospital admissions in the devel-
oped world, in which non-steroidal anti-inflammatory drugs (NSAIDs) and renin-angiotensin system (RAS-) inhibi-
tors are frequently involved. NSAIDs and RAS-inhibitors are also often used in Ghana. The purpose of this study is 
to assess whether biochemical monitoring in patients on RAS-inhibitors, and co-administration of gastro protective 
agents (GPAs) in patients on NSAIDs, is done properly in Ghana. 
Material and methods: Two retrospective cross-sectional studies were carried out at the Agogo Presbyterian Hos-
pital, Ghana, in 2013. In 114 out-and inpatients who are on NSAIDs, the risk for gastrointestinal side effects and the 
frequency of co-administration of GPAs were determined. In 301 outpatients who are on RAS-inhibitors, the risk for 
renal dysfunction and the frequency of biochemical monitoring were determined.  Fisher’s exact test was used to 
determine the statistical strength. 
Results: Co-administration of GPAs was done in 1.8% of patients on NSAIDs. Serum creatinine and potassium 
monitoring within one month after initiation of treatment with RAS-inhibitors were performed in 6.3% and 3.7%, 
respectively. Risk factors were neither associated with prescription of a GPA in patients on NSAIDs (p=0.134), nor 
in performing biochemical monitoring in patients on RAS-inhibitors (p=0.219 for creatinine, p=0.062 for potassi-
um).  
Conclusions: Biochemical monitoring in patients on RAS-inhibitors and use of GPAs in patients on NSAIDs is 
poorly performed at the Agogo Presbyterian Hospital in Ghana. Improving the already existing Ghanaian guidelines, 
especially those for RAS-inhibitors, and encouraging their widespread use among prescribers should be pursued. 
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INTRODUCTION 
Medication use is associated with drug related prob-
lems. Preventable adverse events of medication are an 
important cause of hospital admissions in the developed 
world.1 In addition, studies on hospital care in devel-
oped countries have shown an adverse event rate of 
about 10% in patients admitted to hospitals, with many 
of these medication related.2-8 Little research has been 
done concerning medication related adverse events in 
developing countries.  
 
A study in eight developing African countries found that 
8.2% (2.5 – 18.4 %) of the patients on admission had an 
adverse event, of which 83% were preventable whilst 
about 30% resulted in death. Almost 40% of the adverse 
events were therapeutic errors or drug related. Among 
patients taking any regular drug and patients with chron-
ic illnesses, the adverse event rate is even higher.9 In 
developed countries non-steroidal anti-inflammatory 
drugs (NSAIDs) and renin-angiotensin system (RAS-) 
inhibitors (angiotensin-converting-enzyme (ACE)-
inhibitors and angiotensin-receptor blockers) are among 
the top 4 of drugs most commonly involved in adverse 
drug reactions (ADRs), accounting for 29.6% and 7.7% 
respectively.10 
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NSAIDs can cause serious gastro-intestinal (GI) com-
plications.11,12 To prevent these complications it is im-
portant to assess risk factors and consequently prescribe 
gastro protective agents (GPAs) in high risk pa-
tients.11,13 Guidelines of developed countries recom-
mend that patients who are at high risk should receive 
alternative therapy, or if anti-inflammatory treatment is 
absolutely necessary, co-therapy with a proton-pump 
inhibitor (PPI) or misoprostol. They also recommend to 
use a cyclooxygenase (COX)-2 inhibitor with caution, 
because its use has been limited by its adverse cardio-
vascular side effects.14-16 However, not all high risk pa-
tients receive GPAs. Prescription of an effective GPA is 
seen in only about a third of the high risk patients in 
developed countries.17-19 
 
RAS-inhibitors have many potential beneficial effects 
because of the widespread actions of the renin-
angiotensin-aldosterone system (RAAS): they decrease 
morbidity and mortality in patients with hypertension, 
heart failure and renal disease.20-25 Although they are 
largely considered to be nephroprotective, they can also 
cause serious adverse effects, such as hypotension, hy-
perkalemia and renal function decline.10,14,26-29 Guide-
lines and advisory groups in developed countries recom-
mend monitoring of serum potassium and creatinine 
before initiation of RAS-inhibitors in patients with 
known risk factors. After initiation patients should be 
monitored within two weeks. Some guidelines recom-
mend periodic monitoring, depending on the risk fac-
tors.14,30-32 If there is a risk for hyperkalemia, use of con-
current NSAIDs should be avoided if possible. In spite 
of the largely beneficial effects of RAS-inhibitors, the 
potential risk of kidney failure in high risk patients 
should always be considered.14 In 2006 it was demon-
strated that 68,4% of patients on RAS-inhibitors in the 
US did have at least one serum potassium and one se-
rum creatinine monitoring in a 1-year period.33 In 2011 
it was demonstrated in the Netherlands that, in patients 
who were started on RAS-inhibitors therapy, only 34% 
had serum creatinine level measurements within 3 
weeks after onset of treatment, whilst serum potassium 
level was assessed in only 28% of the patients. In high 
risk patients the frequency of creatinine monitoring was 
even lower, at 22%.34 
 
NSAIDS and RAS-inhibitors are also available and fre-
quently used in Ghana. However, there is hardly any 
literature describing the frequency of their use and 
whether prescribers take into account risk factors when 
deciding to perform biochemical monitoring in patients 
on RAS-inhibitors, and when deciding to co-administer 
GPAs in patients on NSAIDs. A review showed that the 
prevalence of hypertension in Ghana (BP ≥ 140/90 
mmHg) ranged from 19% to 48%.35 Among out-patients 
with hypertension in Ghana, renal disease is an im-
portant complication, especially in those with severe 
hypertension; 30.2% developed a creatinine > 140 
mmol/L.36 Another study in Ghana showed that chronic 
kidney disease (CKD) is common in hypertensive pa-
tients, with a prevalence of 46.9%.37 
 
The Ministry of Health in Ghana has developed Stand-
ard Treatment Guidelines, which are designed to be 
used as a guide on treatment choices and as a reference 
to help in the overall management of patients. The 
guidelines list the preferred treatments for common 
health problems, but give, especially for RAS-
inhibitors, limited advice about monitoring and the safe 
use of medication.38 If preventive measures whilst using 
NSAIDs and RAS-inhibitors are not taken, it may in-
crease the risk of serious nephrotoxicity and GI toxicity, 
which may even be fatal. This presents a dire scenario 
in a developing country like Ghana, where renal re-
placement therapy is mostly not an option and blood 
transfusions for GI bleeding may not always be availa-
ble. There is therefore an urgent need to characterize 
this problem in order to be able to develop and imple-
ment strategies including guidelines which would pro-
mote safe use of NSAIDs and RAS-inhibitors.  
 
METHODS 
Setting 
The study took place at the Agogo Presbyterian Hospital 
in Agogo, Ghana. It is the second largest hospital in the 
Ashanti Region of Ghana and a referral center for many 
hospitals. Although it is officially designated as a dis-
trict hospital, its size, range of service provision and 
service outputs easily place it in the category of regional 
hospitals. It covers the Asante-Akim Area, which spans 
three administrative districts with a population of 
169,976 (2010 census).39 The hospital has 233 beds. 
 
Study population 
NSAID 
Among outpatients, patients aged ≥18 years who visited 
the outpatient department between 16-Oct-2013 and 18-
Dec-2013 and received a prescription of an NSAID 
were included. Inclusion criteria were a new prescrip-
tion of an NSAID for at least 5 days, and one other pre-
scription for an NSAID in the last three months. Among 
inpatients, post-operative patients aged ≥18 years who 
received an NSAID between 08-Oct-2013 and 21-Dec-
2013 were included. They usually receive an NSAID 
initially for about 5-7 days. 
 
RAS-inhibitors 
Patients aged ≥18 years who visited the outpatient de-
partment between 14-Oct-2013 and 04-Dec-2013 and 
received a prescription of a RAS-inhibitor were includ-
Original Article 
 
 
                                                                                                                                                                               
www.ghanamedj.org  Volume 50 Number 1 March 2016 24 
ed. Inclusion criteria were prescription of the RAS-
inhibitor for at least one month.  
 
Data collection 
NSAIDs 
Medical records of outpatients were reviewed in the 
hospital pharmacy, where patients came to pick up their 
new medication after outpatient department (OPD) vis-
its. If patients had a treatment window of more than six 
months, data of the last treatment episode was used for 
the study. Medical records of inpatients were reviewed 
on the two surgical wards and the intensive care unit of 
the hospital, the day after the surgery. Information was 
obtained on demographic characteristics, co-morbidity, 
co-medication, the dose of the NSAID, chronic use (de-
fined as NSAIDs described ≥15 days during the last 
month or a new prescription of ≥15 days) and prescrip-
tion of a GPA. Side effects of GI-bleeding, other bleed-
ing and pain in stomach area, including symptoms of 
epigastric pain, GI ulcer and gastritis, were recorded. 
For inpatients, data was collected on the day after the 
surgery and therefore GI side effects after initiation of 
therapy were not included in the analysis. 
 
RAS-inhibitors 
Medical records were reviewed in the hospital pharma-
cy, where patients came to pick up their new medication 
after OPD visits. If patients had a treatment window of 
more than six months, data of the last treatment episode 
was used for the study. Information was obtained on 
demographic characteristics, co-morbidity, co-
medication, measurements of serum creatinine and po-
tassium within 6 months before start of therapy, and 
measurements of serum creatinine and potassium after 
start of therapy, within and after one month. Side effects 
of high creatinine (serum creatinine level >125.0 
mmol/L) and hyperkalemia (serum potassium level > 
5.4 mmol/L) were recorded. If biochemical monitoring 
was done more than once, the date of the last value be-
fore start of therapy was used, and the date of the first 
value after start of therapy was used for defining the 
time within which monitoring was done.  
 
Prevalence of risk factors 
NSAIDs  
The number of risk factors for GI-problems was deter-
mined. Risk factors for GI-problems included: high dose 
of NSAID, multiple NSAIDs, age > 70 years, history of 
GI-ulcer, co-morbidity of diabetes, heart failure or se-
vere rheumatoid arthritis, concomitant use of anticoagu-
lant, acetyl salicylic acid (including low dose) or corti-
costeroids. The total number of risk factors were enu-
merated. High risk patients were defined as patients 
who have >2 risk factors, are >70 years old or have a 
history of GI-ulcer. 
RAS-inhibitors 
The number of risk factors for renal dysfunction was 
determined. Risk factors included: age > 70 years, co-
morbidity of renal dysfunction, heart failure or diabetes 
mellitus and concomitant use of diuretics or NSAIDs. 
The total number of risk factors were enumerated. High 
risk patients were defined as patients who have >2 risk 
factors. 
 
Ethical consideration 
The Committee on Human Research, Publication and 
Ethics of the Kwame Nkrumah University of Science 
and Technology (KNUST) School of Medical Sciences 
& Komfo Anokye Teaching Hospital in Kumasi, Ghana, 
gave approval for the study. Patient data were collected 
anonymously. 
 
Data analysis 
NSAIDs 
The frequency of a prescription of a GPA was deter-
mined. Fisher’s exact test was used to determine the 
statistical strength of the associations between risk 
groups or single risk factors and prescription of a GPA. 
 
RAS-inhibitors  
The frequencies of serum creatinine and potassium 
monitoring before and after initiation of RAS-inhibitor 
therapy were determined. The main outcome was the 
frequency of biochemical monitoring within 1 month 
after initiation of RAS-inhibitor therapy. Fisher’s exact 
test was used to determine the statistical strength of the 
associations between risk groups or single risk factors 
and biochemical monitoring after initiation of therapy. 
 
Variables that were associated with a p-value lower than 
0.05 were considered statistically significant. Univariate 
analysis was used to calculate odds ratios for the various 
risk groups and single risk factors. All analyses were 
performed using the SPSS statistical software version 
21.0 (SPSS Inc., Chicago, IL, USA). 
 
RESULTS 
NSAIDs 
 
Cohort 
In the timeframe of the study 117 patients received a 
prescription of an NSAID; 53 of them were outpatients. 
3 patients were excluded because of missing data, which 
resulted in a population of 114 patients for the study 
(Table 1). The mean age of the study population was 54 
years (range 18-98 years) and among this population 
55,3% were female. 
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Table 1 Baseline characteristics of patients on NSAID 
Characteristic (NSAID) Value [n (%)] 
Total no. of patients 
Outpatients 
Inpatients 
114 
47 (41.2%) 
67 (58.8%) 
Sex 
Male 
Female 
 
51 (44.7%) 
63 (55.3%) 
Age [y] 54 (18-98)a 
Medical history 
Heart failure 
GI-ulcer 
Diabetes mellitus 
Severe rheumatoid arthritis 
 
2 (1.8%) 
14 (12.3%) 
11 (9.6%) 
0  
Co-medication 
Anticoagulant 
Concomitant acetyl salicylic acid  
Corticosteroids 
 
0  
7 (6.1%) 
0  
Dose 
Normal recommended dose 
High dose 
 
86 (75.4%) 
28 (24.6%) 
Multiple NSAIDs  1 (0.9) 
Risk group gastrointestinal toxicity 
High riskb 
Intermediate riskc  
Low riskd 
 
34 (29.8%) 
25 (21.9%) 
55 (48.2%) 
a mean (range) 
b defined as >2 risk factors, >70 years old or history of GI-ulcer.  
c defined as 1-2 risk factors 
d defined as no risk factors 
 
Gastroprotective agent 
Among all NSAIDs patients, 34 (29.8%) were defined 
as high risk for gastrointestinal toxicity and 25 (21.9%) 
as intermediate risk. GPAs were prescribed in 2 patients 
(1.8%) receiving an NSAID, these were both high risk 
patients. Of the chronic users one out of eight patients 
(12.8%) received a GPA. There was no statistically sig-
nificant association found between the different risk 
groups and the use of a GPA (p = 0.134) (Table 2). Uni-
variate analysis showed that none of the variables were 
associated with prescription of a GPA. 
 
Table 2 Use of gastroprotective agent (GPA) during 
NSAID therapy 
Variable Use of GPA [n (%)]a  
High risk (n=34) 2 (5.9%)  
Intermediate risk (n=25) 0  
Low risk (n=55) 0  
Total (n=114) 2 (1.8%)  
GPA = Gastroprotective agent 
a = Fisher’s exact test: p = 0.134 
 
 
 
Gastrointestinal complaints 
In outpatients who were on NSAIDs, GI-bleedings and 
other bleedings were not seen. Complaints of pain in 
stomach area were seen in 8 patients (17.0%). None of 
these patients was using a GPA. Among high risk pa-
tients 2 patients (5.9%) had complaints of pain in the 
stomach area. 
 
RAS-inhibitors 
 
Cohort 
In the timeframe of the study 305 patients received a 
prescription of a RAS-inhibitor. Of this population, 4 
patients were excluded because of missing data, which 
resulted in a population of 301 patients for the study 
(Table 3). The mean age of the study population was 62 
years (range 22-93 years) and among this population 
73.8% were female. 
 
Table 3 Baseline characteristics of patients on RAS-
inhibitors 
Characteristic (RAS-I) Value [n (%)] 
Total no. of patients 301 
Sex 
Male 
Female 
 
79 (26.2%) 
222 (73.8%) 
Age [y] 62 (22-93)a 
Medical history 
Heart failure 
Chronic kidney disease 
Diabetes mellitus 
 
15 (5.0%) 
7 (2.3%) 
72 (23.9%) 
Co-medication 
NSAIDs 
Loop diuretics 
Thiazide diuretics 
Potassium-sparing diuretics 
 
66 (21.9%) 
12 (4.0%) 
78 (25.9%) 
4 (1.3%) 
Risk group kidney function decline 
High risk (>2 risk factors) 
Intermediate risk (1-2 risk factors) 
Low risk (no risk factors) 
 
19 (6.3%) 
200 (66.4%) 
82 (27.2%) 
a mean (range) 
RAS-I = renin-angiotensin system inhibitor 
 
Serum creatinine and potassium monitoring 
The serum creatinine level was measured in 12 patients 
(4.0%) within less than 6 months before initiation of 
therapy. After initiation of therapy, it was measured in 
19 patients (6.3%) within 1 month and in 57 patients 
(18.9%) at least once after initiation of therapy (table 4). 
The serum potassium level was measured in 4 patients 
(1.3%) within less than 6 months before initiation of 
therapy. After initiation of therapy, it was measured in 
11 patients (3.7%) within 1 month and in 28 patients 
(9.3%) at least once after initiation of therapy (Table 5). 
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Among all RAS-inhibitor patients, 19 (6.3%) were de-
fined as high risk for kidney function decline and 200 
(66.4%) as intermediate risk. Among high risk patients, 
creatinine monitoring was measured in 1 patient (5.3%) 
within 1 month after initiation of therapy. In intermedi-
ate risk patients and low risk patients this was respec-
tively 16 patients (8.0%) and 2 patients (2.4%). Potassi-
um monitoring within 1 month was never measured in 
high risk and low risk patients and in 11 intermediate 
risk patients (5.5%). There was no statistically signifi-
cant association found between the different risk groups 
and creatinine monitoring <6 months before start of 
therapy (p = 0.373), <1 month after start of therapy (p = 
0.219) and ever after start of therapy (p = 0.078) (Table 
4). Univariate analysis showed that none of the varia-
bles were associated with the frequency of creatinine 
monitoring within one month after initiation of therapy. 
 
 
Table 4 Creatinine monitoring in different risk groups before and during renin-angiotensin system inhibitor (RASI) 
therapy 
Variable Monitoring <6 months before start of 
therapy ([n (%)]a 
Monitoring after start of therapy ([n (%)] 
<1 monthb >1 month Totalc 
High risk (n=19) 1 (5.3%) 1 (5.3%) 2 (10.5%) 3 (15.8%) 
Intermediate risk (n=200) 6 (3.0%) 16 (8.0%) 29 (14.5%) 45 (22.5%) 
Low risk (n=82) 5 (6.1%) 2 (2.4%) 7 (8.5%) 9 (11.0%) 
Total (n=301) 12 (4.0%) 19 (6.3%) 38 (12.6%) 57 (18.9%) 
Fisher’s exact test: 
a p = 0.373 
b p = 0.219 
c p = 0.078 
 
There was found a statistically significant association 
between the different risk groups and potassium moni-
toring performed at least once after initiation of therapy 
(p = 0.022). No statistically significant association was 
found between the different risk groups and potassium 
monitoring <6 months before start of therapy (p = 
0.679) and <1 month after start of therapy (p = 0.062) 
(Table 5). Univariate analysis showed that none of the 
variables were associated with the frequency of potassi-
um monitoring within one month after initiation of ther-
apy. 
 
 
Table 5 Potassium monitoring in different risk groups before and during renin-angiotensin system inhibitor (RASI) 
therapy 
Variable Monitoring <6 months before start of 
therapy ([n (%)]a 
Monitoring after start of therapy ([n (%)] 
<1 monthb >1 month Totalc 
High risk (n=19) 0 0 2 (10.5%) 2 (10.5%) 
Intermediate risk (n=200) 2 (1.0%) 11 (5.5%) 13 (6.5%) 24 (12.0%) 
Low risk (n=82) 2 (2.4%) 0 2 (2.4%) 2 (2.4%) 
Total (n=301) 4 (1.3%) 11 (3.7%) 17 (5.6%) 28 (9.3%) 
Fisher’s exact test: 
a p = 0.679 
b p = 0.062 
c p = 0.022 
 
Of the RAS-inhibitor patients, 20 patients (6.6%) re-
ceived the combination of a RAS-inhibitor together with 
a diuretic and an NSAID, the so called ‘triple wham-
my’, what is associated with an increased risk of acute 
kidney injury.40, 41These patients neither had measure-
ment of serum creatinine or potassium within 6 months 
before initiation of therapy nor within 1 month after 
initiation of therapy. In 2 patients (10.0%) serum creati-
nine was measured at least once after initiation of thera-
py.  
 
Serum potassium was never measured after initiation of 
therapy. No statistically significant association was 
found. 
 
Results of biochemical monitoring 
Among all RAS-inhibitor patients there were 2 patients 
(0.7%) who were both monitored for serum creatinine 
within 6 months before and within 1 month after initia-
tion of therapy. These two patients had no kidney func-
tion decline. For serum potassium, there were no pa-
tients who were monitored this way. 
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In patients who had measurement of serum creatinine 
within one month after initiation of therapy, 4 patients 
(25.0%) developed a high serum creatinine within this 
period. These were all intermediate risk patients. In pa-
tients who had at least one measurement of serum creat-
inine after initiation of therapy, 18 patients (31.6%) 
developed a high serum creatinine. These were all in-
termediate risk patients as well. 
 
None of the patients who had measurement of serum 
potassium within one month after initiation of therapy 
developed hyperkalemia within this period. In patients 
who had at least one measurement of serum potassium 
after initiation of therapy, 2 patients (7.1%) developed 
hyperkalemia. These were both intermediate risk pa-
tients. 
 
DISCUSSION 
This is the first study to assess whether prescribers in 
sub-Saharan Africa take into account risk factors in their 
decision to perform biochemical monitoring in patients 
on RAS-inhibitors, and whether co-administration of 
GPAs in patients on NSAIDs is done properly. Alt-
hough the risks of kidney function decline and hyper-
kalemia due to RAS-inhibitors, as well as the GI side 
effects of NSAIDs, are well known, we found that pre-
scribers at the Agogo Presbyterian Hospital barely took 
these risks into account when prescribing these drugs. 
Biochemical monitoring in patients on RAS-inhibitors 
and co-administration of GPAs in patients on NSAIDs 
were scarcely done. 
 
NSAIDs 
Among all patients on NSAIDs, only 2 patients (1.8%) 
received a GPA. None of the five people who were at 
high risk for gastrointestinal toxicity received a GPA. 
Compared with literature from developed countries, that 
reported that about one-third of high risk patients were 
treated with a GPA, the number we found is remarkably 
low.17,18 However, one has to take into account that the 
standard Ghanaian treatment guidelines only recom-
mend a GPA when an NSAID is used for more than two 
weeks.38 So in this respect there was no guideline viola-
tion. However, in the US, Canadian and Dutch guide-
lines there is no duration of NSAID treatment given at 
which one should start a GPA.14,15,42 The national health 
service (NHS) of the United Kingdom has the statement 
that there is an increased risk of serious GI adverse 
events as soon as NSAID treatment is initiated and 
therefore concludes that prescription of a GPA is inde-
pendent of the duration of NSAID use.43 In our study 
there were only 6 out of 114 patients who used  the 
NSAID > 14 days and none of them used GPA. 
 
RAS-inhibitors 
Creatinine monitoring within one month after initiation 
of therapy was only performed in about one-sixteenth 
(6.3%) of the patients. In patients at high risk for renal 
dysfunction this was 5.3%. Potassium monitoring was 
even less frequently done, namely in 3.7% of patients. 
Irrespective of the period since initiation of therapy, 
creatinine was monitored at least once in 18.9% of pa-
tients, potassium in 9.3%. Compared with two other 
studies, which were done only in developed countries, 
these numbers are remarkably low. In a Dutch study, 
serum creatinine monitoring within 3 weeks after initia-
tion of therapy was measured in 34% of patients and in 
a study from the US 68.4% of patients were monitored 
for serum creatinine within 1 year.33,34 The only signifi-
cant association found was the association between the 
risk group categories and potassium monitoring ever 
performed after initiation of therapy. Considering that 
the study did not find rigorous and consistent biochemi-
cal monitoring, this finding was perhaps a chance event.  
High creatinine was found in 21.1% of patients who 
were monitored for serum creatinine within one month 
after initiation of RAS-inhibitor therapy. This suggests 
that among these patients, an important number may 
have kidney function decline. However, there was no 
baseline serum creatinine level known and therefore we 
cannot say anything about whether the use of the RAS-
inhibitor is the cause of high creatinine.  
 
We do not know why prescribers perform so little bio-
chemical monitoring and why there is so little co-
administration of GPAs. A possible cause is that only 
35% of the Ghanaian population has a total active 
membership of the National Health Insurance.44 Moni-
toring of serum creatinine and potassium are reim-
bursed. Although, for the two-third of the population 
who do not have health insurance, it could be that pa-
tients are not able to pay for it or prescribers may con-
sider biochemical monitoring to be too expensive for the 
patients.  
PPIs and H2-antagonists are only covered for treating 
ulcers and not as preventive drugs. This could be the 
reason of the remarkably low number of their prescrip-
tions. Another possible cause may be the lack of appre-
ciation of drug safety and monitoring among prescrib-
ers. Next to that, a possible cause is that there are, espe-
cially for RAS-inhibitors, no clear guidelines. There are 
guidelines in Ghana, which are developed by the Minis-
try of Health, but these are limited: For NSAIDs it is 
mentioned that patients with chronic kidney disease and 
heart failure should not be given NSAIDs, and a PPI 
should be given if treatment is going to exceed 2 weeks. 
There is not much said about biochemical monitoring in 
patients on RAS-inhibitors; the guidelines state that 
serum creatinine is one of the investigations to be per-
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formed when patients are diagnosed with hypertension 
and that potassium should be monitored periodically. 
There is no time frame mentioned.38 This leads to a situ-
ation where every prescriber may take their own indi-
vidual approach. This can result in alterations in medi-
cation with every patient visit, as well as confusion 
among prescribers and patients. Our study was done in a 
hospital which has the capacity to undertake biochemi-
cal monitoring, a service which may be unavailable in 
many district hospitals in Ghana. 
 
The results of this study show that a lot needs to be done 
to improve the safe use of RAS-inhibitors and NSAIDs 
in Ghana. We think that improving the existing Ghana-
ian guidelines and encouraging their widespread use 
among prescribers should be pursued. In order to devel-
op these guidelines it is important to investigate why 
prescribers perform so little biochemical monitoring and 
why they prescribe so little GPAs. Future studies should 
be multi-centered, using hospitals with capacity to un-
dertake biochemical monitoring. While developing the-
se guidelines, it is important to take into account the 
best options suited to the Ghanaian situation, where 
health care has less possibilities than in developing 
countries. It should be noted that in the coming years, 
access to healthcare may improve and the incidence of 
mainly Western diseases will increase.45,46 Consequently 
the incidence of medication related adverse events will 
maybe also increase. 
 
Limitations 
Our study may have several limitations. First, we did 
not investigate whether the prescriber ordered laborato-
ry tests that the patient did not complete. It is possible 
that patients did not want to do an ordered blood test or 
did not understand the need for it. Secondly, handwrit-
ten medical records were used. Mistakes in reading by 
prescribers or by researchers while collecting data is 
possible. Thirdly, the study was performed in one hospi-
tal and with a relatively small number of patients. De-
spite this, we think that our results may also reflect oth-
er hospitals in Ghana and maybe even hospitals in other 
developing countries, because the Agogo Presbyterian 
Hospital is typical in its function as a large district hos-
pital and is a place where patients from a large region in 
the country are seen. Fourthly, we did not have infor-
mation about medication history or laboratory testing 
outside the Agogo Presbyterian Hospital. It is possible 
that this information was known among prescribers, but 
was not recorded in the patient medical record of the 
Agogo Presbyterian Hospital. Lastly, NSAIDs are readi-
ly available in Ghana without prescription. In our study 
we did not have information about the use of non-
prescribed NSAIDs in addition to the prescribed 
NSAIDs. This combination can result in a higher dose 
or a prolonged use and consequently a higher risk for 
kidney function decline and GI toxicity. On the other 
hand, we did not know if patients really used their pre-
scribed medication and whether they used it in the right 
way. 
 
Conclusions 
We demonstrated that biochemical monitoring in pa-
tients on RAS-inhibitors and co-administration of GPAs 
in patients on NSAIDs is poorly performed. The low 
numbers of biochemical monitoring and co-
administration of GPAs clearly demonstrate the need for 
improvement. Especially in Ghana, where healthcare 
options may be limited, this is a serious situation. Our 
findings stress the need to investigate in a multi-
centered study why these numbers are so low. However, 
one has to take into account that the standard Ghanaian 
treatment guidelines only recommend a GPA when an 
NSAID is used for more than two weeks.38 So in this 
respect there was no guideline violation. Improving the 
already existing Ghanaian guidelines, especially those 
for RAS-inhibitors, and encouraging their widespread 
use among prescribers should be pursued. 
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